A new study examines whether dexrazoxane provides cardiac protection in pediatric patients with acute myeloid leukemia (AML).
Using dexrazoxane can provide effective cardioprotection in children with acute myeloid leukemia (AML), according to a new study in the Journal of Clinical Oncology.1
The study was a multicenter study of all patients with AML but without high allelic ratio FLT3/ITD who were treated in Children’s Oncology Group trial AAML1031 between 2011 and 2016. The median length of follow-up was 3.5 years. The administration of dexrazoxane was done at the discretion of treating physicians and was documented at each course.
A total of 1014 patients were included in the study and 96 were give dexrazoxane at every anthracycline course. Compliance with cardiac monitoring, treatment arm, presenting white blood count, sex, race, and age had similar distributions among dexrazoxane-exposed and unexposed patients. Investigators found that dexrazoxane-exposed patients had significantly smaller declines in ejection fraction and shortening fraction than patients who had no exposure as well as a lower risk of left ventricular systolic dysfunction. The 5-year event free survival and overall survival was the same between the exposed group and the unexposed group, with a suggestion of lower treatment-related mortality among patients with dexrazoxane.
The researchers concluded that dexrazoxane worked to preserve cardiac function in children with AML without increasing noncardiac toxicity and should be kept in consideration for cardioprotection during treatment of AML.
1. Getz KD, Sung L, Alonzo TA, Leger KJ, Gerbing RB, Pollard JA. Effect of dexrazoxane on left ventricular systolic function and treatment outcomes in patients with acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol. April 28, 2020. Epub ahead of print. doi: 10.1200/JCO.19.02856
Study finds Black infants with heart abnormalities more likely to die within first year
September 27th 2024A study presented at the AAP 2024 National Conference & Exhibition finds Black infants are 40% more likely to die from congenital heart disease than White infants, highlighting persistent racial health disparities.
Having "the talk" with teen patients
June 17th 2022A visit with a pediatric clinician is an ideal time to ensure that a teenager knows the correct information, has the opportunity to make certain contraceptive choices, and instill the knowledge that the pediatric office is a safe place to come for help.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.